1. Home
  2. FXHO vs VRCA Comparison

FXHO vs VRCA Comparison

Compare FXHO & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FXHO

UTime Limited Class A Ordinary Shares

N/A

Current Price

$11.58

Market Cap

83.2M

Sector

N/A

ML Signal

N/A

Logo Verrica Pharmaceuticals Inc.

VRCA

Verrica Pharmaceuticals Inc.

HOLD

Current Price

$5.23

Market Cap

88.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FXHO
VRCA
Founded
N/A
2013
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
83.2M
88.0M
IPO Year
2019
2018

Fundamental Metrics

Financial Performance
Metric
FXHO
VRCA
Price
$11.58
$5.23
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$17.00
AVG Volume (30 Days)
151.5K
99.9K
Earning Date
N/A
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$35,577,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$94.44
P/E Ratio
N/A
N/A
Revenue Growth
N/A
370.22
52 Week Low
$8.17
$3.28
52 Week High
$25.00
$9.82

Technical Indicators

Market Signals
Indicator
FXHO
VRCA
Relative Strength Index (RSI) 49.99 50.84
Support Level $8.74 $4.52
Resistance Level $13.56 $5.94
Average True Range (ATR) 1.41 0.41
MACD 0.35 0.06
Stochastic Oscillator 69.99 53.60

Price Performance

Historical Comparison
FXHO
VRCA

About FXHO UTime Limited Class A Ordinary Shares

UTime Ltd is engaged in the design, development, production, sales and brand operation of mobile phones, accessories and related consumer electronics. It also provides Electronics Manufacturing Services (EMS), including Original Equipment Manufacturer (OEM) and Original Design Manufacturer (ODM) services, for renowned brands. The company operates in China and its products are sold globally, including Mexico, Brazil, the United States, and other emerging markets in South Asia and Africa as well as Europe. It has two in-house brands, UTime, known as its middle-to-high end label and targets middle class consumers from emerging markets; as its low- to mid-end brand, is positioned to the grassroots consumers and price-sensitive consumers in emerging markets.

About VRCA Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.

Share on Social Networks: